SCHEMBL170055

SCHEMBL170055

O=C(O)Nn1ccnn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20816104 0.84
SCHEMBL8815053 0.84
SCHEMBL4554895 0.79 TSHR (0.31)
SCHEMBL15751967 0.73 MAPT (0.43)
SCHEMBL14678290 0.71
SCHEMBL3912744 0.71
SCHEMBL3367644 0.70
SCHEMBL20548163 0.70 SMN1; SMN2 (0.39)
SCHEMBL5828254 0.70 FOLH1 (0.34)
SCHEMBL6395056 0.70 FOLH1 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1614 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3027776-B1 METHODS AND MOLECULAR PHARMACODYNAMIC BIOMARKERS FOR MULTIPLE SIGNALING PATHWAYS IN RESPONSE TO CARBOXYAMIDOTRIAZOLE OROTATE TACTICAL THERAPEUTICS INC (US) 2024-02-07 EP claimed
US-20230056203-A1 METHODS AND COMPOSITIONS FOR TARGETING CANCER CELLS IN METASTASES THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-02-23 US claimed
EP-3268744-B1 PD-ECGF AS BIOMARKER OF CANCER FUNDACIO INST DINVESTIGACIO BIOMEDICA DE BELLVITGE IDIBELL (ES) 2021-08-11 EP claimed
EP-3191114-B1 OCCIDIOFUNGIN FORMULATIONS AND USES THEREOF UNIV MISSISSIPPI STATE (US) 2021-03-03 EP claimed
EP-3102244-B1 ANTIBODY-DRUG CONJUGATES AND IMMUNOTOXINS ONCOMATRYX BIOPHARMA S L (ES) 2020-03-18 EP claimed
US-10385139-B2 Murine, chimeric, humanized or human anti-TNF-alpha antibodies IBC PHARMACEUTICALS, INC. (US) 2019-08-20 US claimed
EP-2805945-B1 Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors MSD ITALIA SRL (IT) 2019-04-03 EP claimed
EP-2504035-B1 COMPOSITIONS AND METHODS FOR INHIBITING CELLULAR ADHESION OR DIRECTING DIAGNOSTIC OR THERAPEUTIC AGENTS TO RGD BINDING SITES ALLEGRO PHARMACEUTICALS INC (US) 2019-03-27 EP claimed
EP-3102606-B1 ANTIBODY-DRUG CONJUGATES AND IMMUNOTOXINS ONCOMATRYX BIOPHARMA S L (ES) 2018-09-12 EP claimed
US-10022427-B2 Interferon lambda-antibody complexes IBC PHARMACEUTICALS, INC. (US) 2018-07-17 US claimed
US-20010038826-A1 Formulation and method for treating neoplasms by inhalation ZIVENA, INC. 2001-11-08 US claimed
US-20010038827-A1 Formulation and method for treating neoplasms by inhalation ZIVENA, INC. 2001-11-08 US claimed
US-20010036444-A1 Formulation and method for treating neoplasms by inhalation ZIVENA, INC. 2001-11-01 US claimed
WO-2001052868-A1 COMBINATIONS FOR TREATING NEOPLASMS YU BAOFA (US) 2001-07-26 WO claimed
EP-0954283-A2 FORMULATION AND METHOD FOR TREATING NEOPLASMS BY INHALATION BATTELLE MEMORIAL INSTITUTE (US) 1999-11-10 EP claimed
EP-0750637-B1 DNA ENCODING CAI RESISTANCE PROTEINS AND USES THEREOF US HEALTH (US) 1998-12-30 EP claimed
WO-1998029110-A2 FORMULATION AND METHOD FOR TREATING NEOPLASMS BY INHALATION BATTELLE MEMORIAL INSTITUTE (US) 1998-07-09 WO claimed
US-5652223-A DNA encoding CAI resistance proteins and uses thereof THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1997-07-29 US claimed
EP-0750637-A1 DNA ENCODING CAI RESISTANCE PROTEINS AND USES THEREOF THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services (US) 1997-01-02 EP claimed
WO-1995025125-A1 DNA ENCODING CAI RESISTANCE PROTEINS AND USES THEREOF THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1995-09-21 WO claimed